A detailed history of Rhumbline Advisers transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 372,432 shares of ARWR stock, worth $7.31 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
372,432
Previous 383,029 2.77%
Holding current value
$7.31 Million
Previous $9.95 Million 27.57%
% of portfolio
0.01%
Previous 0.01%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$19.36 - $29.54 $205,157 - $313,035
-10,597 Reduced 2.77%
372,432 $7.21 Million
Q2 2024

Aug 01, 2024

BUY
$21.87 - $28.24 $238,907 - $308,493
10,924 Added 2.94%
383,029 $9.95 Million
Q1 2024

May 09, 2024

BUY
$27.21 - $39.48 $1.35 Million - $1.96 Million
49,736 Added 15.43%
372,105 $10.6 Million
Q4 2023

Feb 08, 2024

SELL
$21.2 - $31.03 $392,157 - $573,992
-18,498 Reduced 5.43%
322,369 $9.86 Million
Q3 2023

Nov 09, 2023

SELL
$26.2 - $36.08 $72,233 - $99,472
-2,757 Reduced 0.8%
340,867 $9.16 Million
Q2 2023

Aug 08, 2023

SELL
$25.16 - $41.38 $46,822 - $77,008
-1,861 Reduced 0.54%
343,624 $12.3 Million
Q1 2023

May 11, 2023

SELL
$23.68 - $38.51 $17,665 - $28,728
-746 Reduced 0.22%
345,485 $8.78 Million
Q4 2022

Feb 14, 2023

BUY
$28.0 - $40.56 $507,808 - $735,596
18,136 Added 5.53%
346,231 $14 Million
Q3 2022

Nov 10, 2022

BUY
$29.63 - $48.31 $355,085 - $578,947
11,984 Added 3.79%
328,095 $10.8 Million
Q2 2022

Aug 11, 2022

BUY
$27.79 - $50.61 $739,464 - $1.35 Million
26,609 Added 9.19%
316,111 $11.1 Million
Q1 2022

May 12, 2022

BUY
$39.62 - $69.97 $267,593 - $472,577
6,754 Added 2.39%
289,502 $13.3 Million
Q4 2021

Feb 10, 2022

SELL
$58.09 - $82.51 $7,667 - $10,891
-132 Reduced 0.05%
282,748 $18.7 Million
Q3 2021

Nov 12, 2021

BUY
$58.38 - $84.96 $55,694 - $81,051
954 Added 0.34%
282,880 $17.7 Million
Q2 2021

Aug 05, 2021

SELL
$62.15 - $90.32 $438,219 - $636,846
-7,051 Reduced 2.44%
281,926 $23.3 Million
Q1 2021

May 06, 2021

SELL
$61.35 - $90.47 $531,475 - $783,741
-8,663 Reduced 2.91%
288,977 $19.2 Million
Q4 2020

Feb 10, 2021

SELL
$43.82 - $85.37 $94,081 - $183,289
-2,147 Reduced 0.72%
297,640 $22.8 Million
Q3 2020

Nov 12, 2020

SELL
$33.21 - $51.27 $1.11 Million - $1.72 Million
-33,478 Reduced 10.05%
299,787 $12.9 Million
Q2 2020

Aug 13, 2020

BUY
$26.12 - $43.27 $572,916 - $949,084
21,934 Added 7.05%
333,265 $14.4 Million
Q1 2020

May 06, 2020

BUY
$20.56 - $63.12 $122,475 - $376,005
5,957 Added 1.95%
311,331 $8.96 Million
Q4 2019

Feb 05, 2020

BUY
$28.14 - $73.01 $534,997 - $1.39 Million
19,012 Added 6.64%
305,374 $19.4 Million
Q3 2019

Oct 23, 2019

BUY
$26.26 - $34.86 $87,078 - $115,595
3,316 Added 1.17%
286,362 $8.07 Million
Q2 2019

Aug 14, 2019

BUY
$17.43 - $28.82 $2.77 Million - $4.58 Million
158,770 Added 127.76%
283,046 $7.5 Million
Q1 2019

May 01, 2019

BUY
$12.05 - $20.18 $100,171 - $167,756
8,313 Added 7.17%
124,276 $2.28 Million
Q4 2018

Jan 31, 2019

BUY
$10.74 - $19.7 $398,969 - $731,815
37,148 Added 47.13%
115,963 $1.44 Million
Q3 2018

Nov 07, 2018

SELL
$14.0 - $20.3 $72,338 - $104,890
-5,167 Reduced 6.15%
78,815 $1.51 Million
Q2 2018

Aug 06, 2018

BUY
$6.37 - $14.02 $534,965 - $1.18 Million
83,982 New
83,982 $1.14 Million

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.08B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.